Roche (VTX:ROG) PT Set at CHF 254 by Deutsche Bank

Deutsche Bank set a CHF 254 price objective on Roche (VTX:ROG) in a research report sent to investors on Friday, November 17th. The firm currently has a neutral rating on the healthcare company’s stock.

Other analysts also recently issued reports about the company. Goldman Sachs Group set a CHF 335 price target on Roche and gave the stock a buy rating in a research report on Thursday, August 24th. J P Morgan Chase & Co restated a buy rating and issued a price target on shares of Roche in a research report on Monday, October 16th. Baader Bank set a CHF 231 target price on Roche and gave the stock a neutral rating in a research note on Thursday, October 19th. Kepler Capital Markets set a CHF 230 target price on Roche and gave the stock a neutral rating in a research note on Monday, September 11th. Finally, Sanford C. Bernstein set a CHF 284 target price on Roche and gave the stock a buy rating in a research note on Thursday, July 27th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. Roche presently has an average rating of Hold and a consensus price target of CHF 260.56.

Roche (ROG) traded down CHF 1.90 during trading on Friday, reaching CHF 245.10. 1,830,000 shares of the company traded hands, compared to its average volume of 1,740,000. Roche has a one year low of CHF 218.30 and a one year high of CHF 273.

ILLEGAL ACTIVITY WARNING: “Roche (VTX:ROG) PT Set at CHF 254 by Deutsche Bank” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/05/deutsche-bank-ag-analysts-give-roche-holding-ltd-rog-a-chf-254-price-target-2.html.

About Roche

Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Analyst Recommendations for Roche (VTX:ROG)

Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply